Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bosentan in Early Systemic Sclerosis
NCT00226889Phase 2Terminated
- Sponsor
- Rikshospitalet
- Start
- Jan 2005
- Primary completion
- Jan 2009
- Modality
- Nucleic Acid-Directed Small Molecules, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bosentan in systemic sclerosis (SSc), sponsored by Rikshospitalet. Primary endpoints: Overall clinical progression at 24 months and Degree of deposition of ET-1 in skin at 24 months. Started Jan 2005; status: terminated.
02
Drugs
bosentan
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00226889.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00226889.